glp-1/gip dual agonist weight loss Effects, working principles and target tissues of agonists PDB-101: Molecule of the Month:
Description
doi: 10.1056/NEJMOA1603827 37 LeRNguyenMTAllahwalaMAPsaltisJPMaratheCSMaratheJAet al
Peptides (2018) 99:99107
518,519,520,521 Hepatocellular carcinoma (HCC) Initially developed for treating diabetes, GLP-1RAs have shown potential in treating NASH, which is closely related to HCC
One 2025 study found users lost around 7.7% of body weight after one year, compared to higher numbers seen in randomized trials
Deng, F
Some, like liraglutide, had chemical tweaks and those fatty acid chains that made them stick to albumin
